Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Gains from Investment Securities (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Gains from Investment Securities for 6 consecutive years, with -$87000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 100.29% to -$87000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$43000.0, a 100.14% decrease, with the full-year FY2025 number at -$43000.0, down 100.14% from a year prior.
  • Gains from Investment Securities was -$87000.0 for Q4 2025 at Pliant Therapeutics, down from $44000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $29.7 million in Q4 2024 to a low of -$29.7 million in Q3 2024.
  • A 4-year average of $2.5 million and a median of $125500.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 203.94% in 2022; the steepest drop was 225.93% in 2022.
  • Pliant Therapeutics' Gains from Investment Securities stood at $914000.0 in 2021, then plummeted by 225.93% to -$1.2 million in 2022, then surged by 2684.19% to $29.7 million in 2024, then plummeted by 100.29% to -$87000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Gains from Investment Securities are -$87000.0 (Q4 2025), $44000.0 (Q3 2025), and $29.7 million (Q4 2024).